Loading organizations...
International Medical Industries (IMI), based in Pompano Beach, Florida, designs, develops, and manufactures sterile and non-sterile single-use medical devices focused on drug security and pharmacy compounding. The organization specializes in tamper-evident technologies, such as its Prep-Lock caps, engineered to prevent drug diversion and misuse, thereby enhancing patient safety across various healthcare settings. IMI's American-made products serve compounding pharmacies, hospitals, and home health providers, supporting medication safety and regulatory compliance. All manufacturing occurs at its FDA-registered and ISO 13485 certified facility, with its MDSAP certification valid until September 25, 2028. The company, which has been in operation for over five decades, recently partnered with Integrated Medical Systems (IMS) to expand its tamper-evident product offerings into the home health market. IMI was founded in 1969; the names of its founders are not publicly disclosed.
Key people at IMI.
IMI was founded in 1969 by George Kynoch (Founder).
IMI was founded in 1969 by George Kynoch (Founder).
Key people at IMI.
IMI plc is a UK-based engineering company founded in 1862, specializing in designing, manufacturing, and servicing engineered products that control the precise movement of fluids in extreme environments.[1][2][3] Headquartered in Birmingham, it operates across sectors like process automation, industrial automation, climate control, life sciences, fluid control, and transportation, delivering solutions for LNG production, biopharma, zero-emissions vehicles, and more, with a market capitalization of $5.22 billion and strong financials including 23.50% return on equity and £280.25 million free cash flow.[1][2][3]
The company serves critical industries by providing flow control systems, severe service valves, pneumatic actuation, emission-reduction tech for vehicles, heating/cooling systems, and medical devices, aligning with sustainability trends while maintaining a 1.49% dividend yield and analyst consensus of 11 buy ratings.[1][2]
IMI traces its roots to 1862 as Imperial Metal Industries Limited, evolving into IMI plc in December 1978.[1][2] From its Birmingham base, it grew into a global engineering leader, expanding from metal industries to specialty machinery focused on fluid control in harsh conditions like high temperatures and pressures.[1][3]
Key leadership includes Chairman James Robert Provan Pike (since 2025), CFO Daniel J. Shook (since 2015), and independent directors like Anne Thorburn and Ajai Puri, guiding its shift toward innovative sectors such as sustainable energy and biopharma.[2]
IMI rides trends in sustainability and industrial automation, capitalizing on global shifts toward zero-emissions vehicles, LNG efficiency, and biopharma processing amid energy transitions and climate goals.[1][2] Timing aligns with rising demand for fluid control in extreme environments, fueled by market forces like decarbonization and supply chain resilience in oil/gas, renewables, and EVs.[1]
It influences the ecosystem by enabling smart factories, reducing vehicle emissions, and supporting medical innovations, positioning as a key enabler for industrial tech amid analyst confidence in its navigation of sector challenges.[1][3]
IMI's trajectory points to sustained growth through reinvestment of strong cash flows into acquisitions, R&D for green tech, and shareholder returns, bolstered by its innovation pipeline in emissions tech and automation.[1] Trends like electrification, biopharma expansion, and energy efficiency will shape its path, potentially evolving its influence as a sustainability leader in industrial engineering. This builds on its 160+ year legacy of fluid control excellence, delivering reliable solutions across diverse sectors.[1][2][3]
